NEOS THERAPEUTICS, INC.

Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

Retrieved on: 
Friday, March 12, 2021
NEOS – The New Austria and Liberal Forum, Neos, Political parties, Political organizations

Neos also has a development candidate, NT0502, for the treatment of sialorrhea in patients with neurological conditions.

Key Points: 
  • Neos also has a development candidate, NT0502, for the treatment of sialorrhea in patients with neurological conditions.
  • This communication discusses the proposed merger transaction pursuant to the terms of the Agreement and Plan of Merger, dated as of December 10, 2020, by and among Neos Therapeutics, Inc. (Neos), Aytu BioScience, Inc. (Aytu), and Neutron Acquisition Sub, Inc. (the Merger Agreement).
  • The registration statement was declared effective on February 9, 2021 and the joint proxy statement/prospectus was first mailed to stockholders of Neos and Aytu on or about February 12, 2021.
  • Aytu and Neos also plan to file other relevant documents with the SEC regarding the proposed merger transaction.

Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

Retrieved on: 
Wednesday, March 10, 2021
Corporate finance, NEOS – The New Austria and Liberal Forum, Neos, Mergers and acquisitions, Political parties, Political organizations

In recommending Neos stockholders vote FOR the merger, ISS concluded in its March 8, 2021 report:

Key Points: 
  • In recommending Neos stockholders vote FOR the merger, ISS concluded in its March 8, 2021 report:
    The [Neos] board conducted a thorough sales process, the strategic rationale for the merger is sound, and market reaction to the merger has been strong.
  • This communication discusses the proposed merger transaction pursuant to the terms of the Agreement and Plan of Merger, dated as of December 10, 2020, by and among Neos Therapeutics, Inc. (Neos), Aytu BioScience, Inc. (Aytu), and Neutron Acquisition Sub, Inc. (the Merger Agreement).
  • Aytu and Neos also plan to file other relevant documents with the SEC regarding the proposed merger transaction.
  • Copies of the documents filed by Neos with the SEC will be available free of charge on Neos website at www.

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021

Retrieved on: 
Wednesday, February 10, 2021
Shareholders, Proxy, Neos, NEOS – The New Austria and Liberal Forum, Political parties, Political organizations

Stockholders of record of each company as of February 5, 2021 will be eligible to receive notice of and to vote at their respective companys special meeting.

Key Points: 
  • Stockholders of record of each company as of February 5, 2021 will be eligible to receive notice of and to vote at their respective companys special meeting.
  • The joint proxy statement/prospectus, which is publicly available, will first be mailed to Aytu stockholders and Neos stockholders on or about February 12, 2021.
  • If Neos stockholders of record have any questions or need assistance voting, please contact MacKenzie Partners, Inc., Neos proxy solicitor, by calling (800) 322-2885 or by email to [email protected] .
  • Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs.

Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference

Retrieved on: 
Monday, January 4, 2021
Neos

DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference.

Key Points: 
  • DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference.
  • A replay of the webcast will be available on Neos website for 30 days.
  • Neos Therapeutics, Inc. is a commercial-stage pharmaceutical company developing and manufacturing central nervous system (CNS)-focused products.
  • Neos also has a development candidate, NT0502, for the treatment of sialorrhea in patients with neurological conditions.

Lifshitz Law Firm, P.C. Announces Investigation of AJRD, CATM, EXPC, GNBF, LNKB, NEOS, AYTU, QEP, FANG, RP, RNET, and VSAT

Retrieved on: 
Friday, December 25, 2020
Common law, Equity, Fiduciary, Lifshitz

If you are an AJRD investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are an AJRD investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • announces investigation into possible breach of fiduciary duties in connection with the sale of CATM for $35.00 per share.
  • If you are a CATM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • The law firm responsible for this advertisement is Lifshitz Law Firm, P.C., 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780.

NEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Neos Therapeutics, Inc. - NEOS

Retrieved on: 
Thursday, December 17, 2020
Foti, NEOS – The New Austria and Liberal Forum, Neos, Airlines, Political parties, Political organizations

and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Neos Therapeutics, Inc. (NasdaqGS: NEOS) to Aytu BioScience, Inc. (NasdaqGS: AYTU).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Neos Therapeutics, Inc. (NasdaqGS: NEOS) to Aytu BioScience, Inc. (NasdaqGS: AYTU).
  • Under the terms of the proposed transaction, shareholders of Neos will receive only 0.1088 shares of Aytu for each share of Neos that they own.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/neos-therapeutics-investor-alert...
    SOURCE Kahn Swick & Foti, LLC

Neos Therapeutics Reports Third Quarter 2020 Financial Results

Retrieved on: 
Monday, November 9, 2020
NEOS – The New Austria and Liberal Forum, Political parties, NASDAQ, Political organizations, Finance

Selling and marketing expenses were $4.8 million for the three months ended September 30, 2020, compared to $7.1 million for the same period in 2019.

Key Points: 
  • Selling and marketing expenses were $4.8 million for the three months ended September 30, 2020, compared to $7.1 million for the same period in 2019.
  • For the third quarter of 2020, net loss was $4.9 million, or ($0.10) per share, compared to $2.1 million, or ($0.04) per share, in the third quarter of 2019.
  • Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m.
  • Neos Therapeutics, Inc.(NASDAQ: NEOS) is a commercial-stage pharmaceutical company developing and manufacturing central nervous system (CNS)-focused products.

Neos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020

Retrieved on: 
Monday, November 2, 2020
NEOS – The New Austria and Liberal Forum, Neos, Political parties, Political organizations, Politics of Europe

DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its third quarter 2020 financial results at the opening of U.S. financial markets on Monday, November 9, 2020.

Key Points: 
  • DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its third quarter 2020 financial results at the opening of U.S. financial markets on Monday, November 9, 2020.
  • Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m.
  • The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 8053068.
  • Neos Therapeutics, Inc. (NASDAQ: NEOS) is a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products.

Neos Therapeutics to Present at Cantor Virtual Global Healthcare Conference

Retrieved on: 
Wednesday, September 9, 2020
Neos, NEOS – The New Austria and Liberal Forum, Political parties, Political organizations, Politics of Europe

DALLAS and FORT WORTH, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020, at 3:40 p.m.

Key Points: 
  • DALLAS and FORT WORTH, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020, at 3:40 p.m.
  • A live webcast of the fireside chat will be available on the Investor Relations page of the companys website at http://investors.neostx.com/ .
  • Following the presentation, a replay of the webcast will be available on Neos website for 30 days.
  • Neos Therapeutics, Inc.(NASDAQ: NEOS) is a commercial-stage pharmaceutical company developing and manufacturing central nervous system (CNS)-focused products.

Neos Therapeutics Reports Second Quarter 2020 Financial Results

Retrieved on: 
Monday, August 10, 2020
NEOS – The New Austria and Liberal Forum, Neos, NASDAQ, Political parties, Finance, Political organizations

Total costs of the reduction-in-force implemented in May 2020, inclusive of the sales and marketing expense, was approximately $1.1 million.

Key Points: 
  • Total costs of the reduction-in-force implemented in May 2020, inclusive of the sales and marketing expense, was approximately $1.1 million.
  • For the second quarter of 2020, net loss was $5.5 million or ($0.11) per share, compared to $3.8 million, or ($0.08) per share in the second quarter of 2019.
  • Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. EDT today.
  • Neos Therapeutics, Inc.(NASDAQ: NEOS) is a commercial-stage pharmaceutical company developing and manufacturing central nervous system (CNS)-focused products.